Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | ADH1B | P00325 | 2/20 | 0.41 |
| ▸ | ADH1C | P00326 | 2/20 | 0.41 |
| ▸ | ADH1A | P07327 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ADH4 | P08319 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3016934 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B10SIGMAR1EPHX1CYP3A4 | |
| SCHEMBL13166304 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B10SIGMAR1EPHX1CYP3A4 | |
| SCHEMBL13166302 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B10SIGMAR1EPHX1CYP3A4 | |
| SCHEMBL8921740 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B10SIGMAR1EPHX1CYP3A4 | |
| SCHEMBL1148684 | 1.00 | — | — | |
| SCHEMBL1485899 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B10SIGMAR1EPHX1CYP3A4 | |
| SCHEMBL13166298 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B10SIGMAR1EPHX1CYP3A4 | |
| SCHEMBL3036481 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B10SIGMAR1EPHX1CYP3A4 | |
| SCHEMBL8918 | 1.00 | — | — | |
| SCHEMBL3035987 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HSD17B10SIGMAR1EPHX1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435375-B2 | CXCR4 chemokine receptor modulators | NORTHWESTERN UNIVERSITY (US) | 2019-10-08 | — | — | US | disclosed |
| EP-3424527-A1 | DIAGNOSTIC METHOD | AVA Lifescience GmbH (DE) | 2019-01-09 | — | — | EP | disclosed |
| US-20180155295-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | NORTHWESTERN UNIVERSITY | 2018-06-07 | — | — | US | disclosed |
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-7803804-B2 | Substituted pyrazines for use in the treatment of inflammatory or allergic conditions | NOVARTIS AG (CH) | 2010-09-28 | — | — | US | disclosed |
| US-20100028368-A1 | SULFIDE, SULFOXIDE AND SULFONE CHALCONE ANALOGUES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2010-02-04 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| US-20080312217-A1 | Organic Compounds | NOVARTIS AG | 2008-12-18 | — | — | US | disclosed |
| WO-2007071396-A2 | PYRAZINOYLGUANIDINE COMPOUNDS USEFUL IN THE TREATMENT OF INFLAMMATORY OR ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435375-B2 | CXCR4 chemokine receptor modulators | CXCR4, ACKR3, CXCR3 | ALDH1A1 2896/4885HSD17B10 3696/4885SIGMAR1 354/4885 |
| US-20100028368-A1 | SULFIDE, SULFOXIDE AND SULFONE CHALCONE ANALOGUES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF | SULT1E1, RPS3A, SULT1A1 | ALDH1A1 708/4885HSD17B10 370/4885SIGMAR1 1330/4885 |
| US-20180155295-A1 | CXCR4 CHEMOKINE RECEPTOR MODULATORS | CXCR4, ACKR3, CXCR3 | ALDH1A1 2896/4885HSD17B10 3696/4885SIGMAR1 354/4885 |
| US-20080312217-A1 | Organic Compounds | TRPA1, TRPV1, CHRM1 | ALDH1A1 567/4885HSD17B10 3142/4885SIGMAR1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.